Geron Corp(GERN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 27 at 7:49 PM ET (Korea 10/28 08:49)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.1 | Insider Own | 1.43% | Shs Outstand | 642.5M | Perf Week | -7.26% |
| Market Cap | 0.74B | Forward P/E | 15.54 | EPS next Y | 264.44% | Insider Trans | - | Shs Float | 633.3M | Perf Month | -8% |
| Enterprise Value | 0.69B | PEG | - | EPS next Q | -0.01 | Inst Own | 73.23% | Short Float | 11.78% | Perf Quarter | -17.86% |
| Income | -0.07B | P/S | 3.61 | EPS this Y | 65.38% | Inst Trans | -0.77% | Short Ratio | 7.43 | Perf Half Y | -23.84% |
| Sales | 0.20B | P/B | 3.38 | EPS next 5Y | - | ROA | -13.01% | Short Interest | 74.61M | Perf YTD | -12.88% |
| Book/sh | 0.34 | P/C | 2.44 | EPS past 3/5Y | 30.48% 14.78% | ROE | -29.24% | 52W High | -42.79% ($2.01) | Perf Year | -10.16% |
| Cash/sh | 0.47 | P/FCF | - | Sales past 3/5Y | 575.71% 273.49% | ROIC | -15.58% | 52W Low | 10.58% ($1.04) | Perf 3Y | -35.75% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 21.06% | Gross Margin | 96.45% | Volatility(W/M) | 6.45% 4.45% | Perf 5Y | -20.69% |
| Dividend TTM | - | EV/Sales | 3.36 | Sales Y/Y TTM | 24.39% | Oper. Margin | -18.36% | ATR (14) | 0.06 | Perf 10Y | -42.79% |
| Dividend Ex-Date | - | Quick Ratio | 5.16 | EPS Q/Q | -1.22% | Profit Margin | -34.17% | RSI (14) | 39.31 | Recom | 1.4 |
| Dividend Gr. 3/5Y | - | Current Ratio | 6.92 | Sales Q/Q | 17.22% | SMA20 | -3.62% ($1.19) | Beta | 0.58 | Target Price | $4.25 |
| Payout | - | Debt/Eq | 1.15 | Earnings | 2026/11/4 | SMA50 | -13.42% ($1.33) | Rel Volume | 0.67 | Prev Close | $1.15 |
| Employees | 258 | LT Debt/Eq | 1.05 | EPS/Sales Surpr. | -124.72% 3.94% | SMA200 | -19.67% ($1.43) | Avg Volume(3M) | 10.04M | Price | $1.15 |
| IPO | 1996/7/31 | Option/Short | Yes/Yes | Trades | 18951 | Volume | 6,709,322 | Change | - |
🧬 Geron is a U.S. biotech company that develops and commercializes blood cancer therapeutics centered on telomerase inhibition mechanisms. It focuses on hematologic disease areas such as myelodysplastic syndromes and is positioning itself as a specialized oncology biopharma advancing from clinical development to commercialization.
Over the past 1 year, on the lower side
43% below its 1-year high.
Traded less than usual. That is 67% of its average volume.
Next earnings report: November 4
7 days to go.
GERN has a sound balance sheet but weak earning power
Of every $100 in sales, $18.36 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +65.4% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $361. Peers typically go for $1,261.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -20.7%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 73.2%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #182 of 594 in the industry
Based on market cap of $739M.
FAQ
What kind of company is GERN?
GERN belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of GERN?
The market cap of GERN is approximately $739M, ranking 2,827 within its sector.
What is the 52-week high and low for GERN?
GERN has recorded a 52-week high of $2.01 and a low of $1.04.
